E.F. Hutton arranges $5M public offering for iSpecimen

E.F. Hutton & Co. served as the exclusive placement agent for a $5 million public offering for iSpecimen Inc. (Nasdaq: ISPC), according to a press release issued Aug. 7, 2026.

iSpecimen, which operates an online marketplace connecting medical researchers with biospecimen providers, said the capital raised will be used for repayment of outstanding liabilities, potential acquisitions and investments, marketing initiatives, and general corporate purposes.

The transaction is the third capital markets engagement between E.F. Hutton and iSpecimen since December 2025. E.F. Hutton has acted as exclusive placement agent on each of the financing transactions during that period.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, said: "We are pleased to once again support iSpecimen on another successful financing. This transaction represents our third capital markets engagement with the Company in less than a year, reflecting the strength of our relationship and our shared commitment to supporting innovative healthcare companies as they execute their long-term growth strategies."

E.F. Hutton is a New York City-based investment bank and broker-dealer that serves corporations, financial sponsors, and institutional investors across the U.S., Asia, Europe, the UAE, and Latin America.

You May Also Be Interested In

• iSpecimen Inc. Announces Closing of $5 Million Public Offering of Common Stock and Pre-Funded Warrants
• BlossomHill Therapeutics prices $150M IPO at $16 per share
• River City Bank prices IPO at $45 per share on Nasdaq